8-K: ALX Oncology Reports Q2 Results, Extends Cash Runway

ALX Oncology Holdings Inc. announced its second quarter 2025 financial results, highlighted by an extended cash runway into Q1 2027 and positive biomarker data for its lead oncology programs.

Summary

• ALX Oncology reported a GAAP net loss of ($25.9) million for Q2 2025, an improvement from ($39.4) million in Q2 2024.
• Cash, cash equivalents, and investments stood at $83.5 million as of June 30, 2025, with the cash runway extended into Q1 2027.
• Research and Development (R&D) expenses decreased by $16.6 million to $18.0 million in Q2 2025, primarily due to reduced clinical and development costs, stock-based compensation, and pipeline prioritization.
• General and Administrative (G&A) expenses decreased by $1.4 million to $5.5 million in Q2 2025, mainly due to lower stock-based compensation.
• An impairment charge of $3.175 million was recorded in Q2 2025 related to leased lab space following a workforce reduction.
• Data from the ASPEN-06 trial in gastric cancer identified CD47 overexpression as a key predictive biomarker for evorpacept response, with a 65% objective response rate (ORR) in CD47-high patients compared to 26% with standard therapy.
• The ASPEN-Breast study design for HER2+ breast cancer was amended to a single-arm, biomarker-driven study, with interim data anticipated in Q3 2026.
• The ASPEN-CRC study in colorectal cancer was paused to extend the cash runway.
• The Phase 1 clinical trial for ALX2004, an EGFR-targeted antibody-drug conjugate, is on track to enroll its first patient in August, with initial safety data expected in 1H 2026.
• Daniel Curran, M.D., was appointed as a Class III director to the Board, increasing its size from six to seven directors, and will serve on the Corporate Governance and Nominating Committee.
• Allison Dillon, Ph.D., was appointed Chief Operating Officer, effective August 12, 2025.

Sentiment

Score: 8

Explanation: The sentiment is positive due to improved financial metrics (lower net loss, extended cash runway), promising clinical data guiding future development, and the advancement of a new pipeline candidate. The strategic decision to pause one trial to extend the cash runway is viewed as a prudent move for long-term sustainability and focus on higher-potential programs. The new board appointment also adds significant expertise.

Positives

• GAAP net loss decreased to ($25.9) million in Q2 2025 from ($39.4) million in Q2 2024, indicating improved financial performance.
• Cash runway extended into Q1 2027, providing longer financial stability for ongoing clinical programs.
• Significant reduction in R&D expenses by $16.6 million and G&A expenses by $1.4 million, reflecting effective cost management and pipeline prioritization.
• Positive data from the ASPEN-06 trial identified CD47 expression as a predictive biomarker for evorpacept, showing a 65% ORR in CD47-high HER2+ gastric cancer patients, indicating a clear path for targeted therapy.
• Strategic amendment of the ASPEN-Breast study to a single-arm, biomarker-driven design is expected to optimize enrollment and support a potential registrational study.
• ALX2004 Phase 1 trial is on track to dose its first patient in August, advancing a new pipeline candidate with best-in-class potential and a differentiated safety profile.
• Appointment of Daniel Curran, M.D., to the Board of Directors brings over 25 years of pharmaceutical experience in strategy, business development, and drug development.

Negatives

• An impairment charge of $3.175 million was recorded in Q2 2025 related to leased lab space, indicating a reduction in physical assets or operations.
• The ASPEN-CRC study in colorectal cancer was paused, which may limit the breadth of the evorpacept development program, although it was done to extend cash runway.

Risks

• Forward-looking statements involve substantial risks and uncertainties, and actual results may differ materially from those expressed or implied.
• Risks are described more fully in the company's SEC filings, including Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

The company anticipates patient dosing for the ASPEN-Breast Cancer trial to begin in Q4 2025, with interim data expected in Q3 2026. The ALX2004 Phase 1 trial is set to begin patient dosing in August, with initial safety data anticipated in 1H 2026. The company's strategic prioritizations have extended its cash runway into Q1 2027, supporting these upcoming data milestones.

Management Comments

• "In the second quarter, we made significant advances in both our evorpacept and ALX2004 clinical programs."
• "On the evorpacept program, we are excited to share data demonstrating the potential of CD47 expression as a predictive biomarker and highlight a clear opportunity to identify patients most likely to achieve the greatest benefit."
• "In this pre-planned analysis we saw that patients with high CD47 expression derived the most clinically meaningful response to evorpacept."
• "These findings shape our clinical development strategy in breast cancer and support the potential to pursue targeted oncology approaches in additional tumor types, given the broad overexpression of CD47 in solid tumors and hematologic malignancies."
• "Importantly, our optimization of the evorpacept clinical program has extended our cash runway into the first quarter of 2027, solidly positioning us to achieve multiple data milestones across our pipeline."
• "In addition, execution is on track for the Phase 1 trial of our highly-differentiated, ADC candidate, ALX2004, which has best-in-class potential for the treatment of EGFR-expressing solid tumors and we anticipate dosing the first patient this month."
• "Finally, I am delighted to announce that Dr. Dan Curran has been appointed to the Board of Directors. Dr. Currans illustrious career and breadth of experience across drug discovery and development, corporate strategy and business development, will offer invaluable perspective to help ALX Oncology reach key inflection points in the months ahead."

Industry Context

The oncology biotechnology sector continues to emphasize biomarker-driven therapies to improve patient outcomes and optimize clinical development. ALX Oncology's focus on CD47 as a predictive biomarker for evorpacept aligns with this trend, aiming to identify patient populations most likely to benefit, which can accelerate drug development and increase success rates. The advancement of ALX2004, an ADC with a differentiated safety profile, also positions the company within the competitive and rapidly evolving ADC landscape, seeking to address unmet needs in EGFR-expressing solid tumors.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to extended cash runway, improved financial efficiency, promising clinical data guiding future development, and strategic pipeline prioritization, which could lead to increased long-term value.
• Employees: The prior workforce reduction in preclinical research (March 2025) led to an impairment charge, indicating some impact on employees in that area. The appointment of a new COO may signal internal restructuring for operational excellence.
• Customers (future patients): Positive impact from the advancement of novel therapies like evorpacept and ALX2004, especially with a biomarker-driven approach that aims to provide more effective treatments for specific cancer types.
• Creditors: Extended cash runway provides greater assurance of the company's ability to meet its financial obligations.

Next Steps

• Present full data set from ASPEN-06 trial at a medical conference in Q4 2025.
• Begin patient dosing in the ASPEN-Breast Cancer trial in Q4 2025.
• Begin patient dosing in the ALX2004 Phase 1 clinical trial in August.
• Release initial safety data from ALX2004 Phase 1 trial in 1H 2026.
• Anticipate interim data readout from the ASPEN-Breast trial in Q3 2026.

Key Dates

Recommendation

The company has demonstrated improved financial discipline by reducing operating expenses and extending its cash runway into Q1 2027 through strategic pipeline prioritization. The positive biomarker data from the ASPEN-06 trial for evorpacept provides a clear, de-risked path for future clinical development, particularly in HER2+ breast cancer, which is a significant market. The advancement of ALX2004 into Phase 1 trials adds another promising asset to the pipeline. These factors, combined with the strengthening of the Board with a highly experienced director, suggest a positive outlook for the company's clinical and financial trajectory, making it an attractive investment for growth-oriented investors in the biotech sector.

Keywords

Oncology, Biotechnology, Clinical Trials, Cancer Therapy, Evorpacept, ALX2004, CD47, HER2+ Gastric Cancer, HER2+ Breast Cancer, EGFR-expressing Solid Tumors, SEC Filing, Financial Results, Corporate Governance, Drug Development